Skip to main content
. 2022 Dec 6;15(1):2153410. doi: 10.1080/19420862.2022.2153410

Figure 3.

Mechanisms of action for antibody therapeutics in late-stage clinical studies*. Two Euler diagrams representing the main mechanisms of action of antibodies in late-stage clinical studies, with mechanisms for the antibodies for non-cancer indications on the left and for cancer indications on the right. The majority of the antibodies for either type of indication function via blocking or neutralization of the targeted antigen. Payload delivery and cell engagement are relevant mechanisms only for the antibodies now being evaluated in late-stage studies as treatments for cancer.

Mechanisms of action for antibody therapeutics in late-stage clinical studies*. Area proportional Euler diagrams representing the main mechanisms of action of antibodies in late-stage clinical studies. (a) Antibodies for non-cancer indications. (b) Antibodies for cancer indications. *Data as of October 1, 2022; n = 65 antibodies for non-cancer indications, n = 73 antibodies for cancer indications. Abbreviations: CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody dependent cell phagocytosis. Figure created using euler: Area-Proportional Euler and Venn Diagrams with Ellipses, R package version 6.1.1, available at https://eulerr.co/.